

DAFTAR PUSTAKA

- Australian Group on Antimicrobial Resistance (AGAR). 2018. AGAR Group
<http://www.agargroup.org.au/>.
- Antonanzas F, Lozano C, Torres C. 2015. Economic features of antibiotic resistance: the case of methicillin-resistant *Staphylococcus Jevons* MP. 1961. “Celbenin” -resistant staphylococci. *Br Med J* 1:124 -125.
- Bemis DA, Jones RD, Frank LA, Kania SA. 2009. Evaluation of susceptibility test breakpoints used to predict *mecA*-mediated resistance in *Staphylococcus pseudintermedius* isolated from dogs. *J Vet Diagn Invest* 21:53-58.
<https://doi.org/10.1177/104063870902100108>.
- Black CC, Solyman SM, Eberlein LC, Bemis DA, Woron AM, Kania SA. 2009. Identification of a predominant multilocus sequence type, pulsed-field gel electrophoresis cluster, and novel staphylococcal chromosomal cassette in clinical isolates of *mecA*-containing, methicillin-resistant *Staphylococcus pseudintermedius*. *Vet Microbiol* 139:333-338.
<https://doi.org/10.1016/j.vetmic.2009.06.029>.
- Bynoe ET, Elder RH, Comtois RD. 1956. Phage-typing and antibiotic resistance of staphylococci isolated in a general hospital. *Can J Microbiol* 2:346 -358.
<https://doi.org/10.1139/m56-041>.
- Chen, C. J. & Huang, Y. C. 2014. New epidemiology of *Staphylococcus aureus* infection in Asia. *Clin. Microbiol. Infect.* **20**, 605–623.

- Cowan ST, Shaw C, Williams RE. 1954. Type strain for *Staphylococcus aureus* Rosenbach. *J Gen Microbiol* 10:174 -176. <https://doi.org/10.1099/00221287-10-1-174>.
- David MZ., Daum RS. 2010. Community-associated methicillin-resistant *Staphylococcus aureus* : epidemiology and clinical consequences of an emerging epidemic. *Clinical Microbiology Review*, Vol 23, No.3, hal 616-687
- Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN, Beach M, Group SP. 2001. Survey of infections due to *Staphylococcus* species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. *Clin Infect Dis* 32(Suppl 2):S114 -S132. <https://doi.org/10.1086/320184>.
- Diekema, D. J. et al. 2001. Survey of infections due to *Staphylococcus* species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997–1999. *Clin. Infect. Dis.* **32** (Suppl. 2), S114–S132
- Duerenberg RH., Beisser PS., Visschers MJ. 2010. Molecular typing of Methicillin-Susceptible *Staphylococcus aureus* isolates collected in the Yogyakarta area in Indonesia. *Clinical Microbiology Infections*, Vol 16, hal 92-94.

- Enright, M. C., Day, N. P., Davies, C. E., Peacock, S. J. & Spratt, B. G. 2000. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of *Staphylococcus aureus*. *J. Clin. Microbiol.* **38**, 1008–1015
- Fleming A. 2001. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of *B. influenzae*. 1929. *Bull World Health Organ* 79:780 -790.
- Fooladi AA, Ashrafi E, Tazandareh SG, Koosha RZ, Rad HS, Amin M, et al. 2015. The distribution of pathogenic and toxigenic genes among MRSA and MSSA clinical isolates. *Microb Pathog.*;81:60-66.
- Fortuin-de Smidt MC, Singh-Moodley A, Badat R, Quan V, Kularatne R, Nana T, Lekalakala R, Govender NP, Perovic O, for GERMS-SA. 2015. *Staphylococcus aureus* bacteraemia in Gauteng academic hospitals, South Africa. *Int J Infect Dis* 30:41- 48. <https://doi.org/10.1016/j.ijid.2014.10.011>.
- Gillespie WA, Alder VG. 1957. Control of an outbreak of staphylococcal infection in a hospital. *Lancet* 272:632- 634. [https://doi.org/10.1016/S0140-6736\(57\)91091-7](https://doi.org/10.1016/S0140-6736(57)91091-7).
- Gould D, Chamberlaine A. 1995. *Staphylococcus aureus*: a review of the literature. *J Clin Nurs* 4:5-12. <https://doi.org/10.1111/j.1365-2702.1995.tb00004.x>.

- Grema HA. 2015. Methicillin resistant *Staphylococcus aureus* (MRSA):a review. *Adv Anim Vet Sci* 3:79 -98. <https://doi.org/10.14737/journal.aavs/2015/3.2.79.98>.
- Harkins, C. P. et al. 2017. Methicillin-resistant *Staphylococcus aureus* emerged long before the introduction of methicillin into clinical practice. *Genome Biol.* **18**, 130
- Hassall JE, Rountree PM. 1959. Staphylococcal septicaemia. *Lancet* i:213-217.
- Hayden MK., Lolans K., Haffenreffer K., 2016. Chlorhexidine and Mupirocin Susceptibility of Methicillin-Resistant *Staphylococcus aureus* Isolates in the REDUCE-MRSA Trial, *Journal of Clinical Microbiology*, vol 54, no 11, hal 2735-2740
- Jessen O, Rosendal K, Bulow P, Faber V, Eriksen KR. 1969. Changing staphylococci and staphylococcal infections. A ten-year study of bacteria and cases of bacteremia. *N Engl J Med* 281:627- 635.
- Jevons MP. 1961. "Celbenin" -resistant staphylococci. *Br Med J*1:124 -125.
- Kirby WM. 1944. Extraction of a highly potent penicillin inactivator from penicillin resistant staphylococci. *Science* 99:452- 453. <https://doi.org/10.1126/science.99.2579.452>.
- Klein E, Smith DL, Laxminarayan R. 2007. Hospitalizations and deaths caused by methicillin-resistant *Staphylococcus aureus*, United States, 1999-2005. *Emerg Infect Dis.*;13(12):1840-6.

- Lai, C. C., Lin, S. H., Sheng, W. H. & Hsueh, P. R. 2013. Decrease in the incidence of methicillin-resistant *Staphylococcus aureus* nosocomial bloodstream infections in Taiwan. *Int. J. Antimicrob. Agents* **41**, 591–592.
- Lakhundi S, Zhanga K. 2018. Methicillin-Resistant *Staphylococcus aureus*: Molecular Characterization, Evolution, and Epidemiology. *Clinical Microbiology Review*, Vol 31, Hal 2-4.
- Landau R. 1999. *Pharmaceutical Innovation: Revolutionizing Human Health*. Philadelphia: Chemical Heritage Press.
- Lederberg J. 1957. Mechanism of action of penicillin. *J Bacteriol*, Vol 73, hal 144
- Lindsay JA, Holden MT. 2004. *Staphylococcus aureus*: superbug, super genome? *Trends Microbiol* Vol 12, Hal 378-385. <https://doi.org/10.1016/j.tim.2004.06.004>.
- Loeffler A, Linek M, Moodley A, Guardabassi L, Sung JM, Winkler M, Weiss R, Lloyd DH. 2007. First report of multiresistant, *mecA*-positive *Staphylococcus intermedius* in Europe: 12 cases from a veterinary dermatology referral clinic in Germany. *Vet Dermatol* 18:412- 421. <https://doi.org/10.1111/j.1365-3164.2007.00635.x>.
- Lowy FD. 1998. *Staphylococcus aureus* infections. *The New England Journal of Medicine*, Vol 339, Hal 520-532. <https://doi.org/10.1056/NEJM199808203390806>.
- Lowy FD. 2003. Antimicrobial resistance: the example of *Staphylococcus aureus*. *J Clin Invest* 111:1265-1273. <https://doi.org/10.1172/JCI18535>.

- Mendes, R. E. et al. 2013. Regional resistance surveillance program results for 12 Asia-Pacific nations (2011). *Antimicrob. Agents Chemother.* **57**, 5721–5726.
- Mitchell, B. G., Collignon, P. J., McCann, R., Wilkinson, I. J. & Wells, A. 2014. A major reduction in hospital-onset *Staphylococcus aureus* bacteremia in Australia-12 years of progress: an observational study. *Clin. Infect. Dis.* **59**, 969–975.
- Monecke, S. et al. 2011. A field guide to pandemic, epidemic and sporadic clones of methicillin-resistant *Staphylococcus aureus*. *PLoS ONE* **6**, e17936
- Neushul P. 1993. Science, government, and the mass production of penicillin. *J Hist Med Allied Sci* 48:371–395. <https://doi.org/10.1093/jhmas/48.4.371>.
- Ogston A. 1881. Report upon micro-organisms in surgical diseases. *Br Med J* 1:369–375.
- Rammelkamp CH, Maxon T. 1942. Resistance of *Staphylococcus aureus* to the action of penicillin. *Proc Soc Exp Biol Med* 51:386–389. <https://doi.org/10.3181/00379727-51-13986>.
- Rayner C., Munckhof WJ. 2005. Antibiotics currently used in the treatment of infections cause by *Staphylococcus aureus*. *Internal Medicine Journal*, Vol 35, hal 3-16.
- HA., Severin J., 2016. Characterisation of clinical *Staphylococcus aureus* isolates harbouring *mecA* or Panton-Valentine leukocidin genes from four tertiary

care hospitals in Indonesia. *Tropical Medicine and International Health*.
Vol 21, No 5, hal 610-618

Schito GC. 2006. The importance of the development of antibiotic resistance in
Staphylococcus aureus. *Clin Microbiol Infect* Vol 12(Suppl 1): S3-S8.
<https://doi.org/10.1111/j.1469-0691.2006.01343.x>.

Shanson DC. Antibiotic-resistant *Staphylococcus aureus*. *J Hosp Infect*. 1981;2:11–
36.

Tenover, F. C. et al. 1995. Interpreting chromosomal DNA restriction patterns
produced by pulsed-field gel electrophoresis: criteria for bacterial strain
typing. *J. Clin. Microbiol*. **33**, 2233–2239

Thampi N, Showler A, Burry L, Bai AD, Steinberg M, Ricciuto DR, Bell CM,
Morris AM. 2015. Multicenter study of health care cost of patients
admitted to hospital with *Staphylococcus aureus* bacteremia: impact of
length of stay and intensity of care. *Am J Infect Control* 43:739 -744.
<https://doi.org/10.1016/j.ajic.2015.01.031>.

Tsubakishita S, Kuwahara-Arai K, Sasaki T, Hiramatsu K. 2010. Origin and
molecular evolution of the determinant of methicillin resistance in
staphylococci. *Antimicrob Agents Chemother* 54:4352- 4359.
<https://doi.org/10.1128/AAC.00356-10>.

Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh
HA, Nouwen JL. 2005. The role of nasal carriage in *Staphylococcus*

aureus infections. *Lancet Infect Dis* 5:751–762.

[http://dx.doi.org/10.1016/S1473-3099\(05\)70295-4](http://dx.doi.org/10.1016/S1473-3099(05)70295-4).

Whitby M, McLaws ML, Berry G. 2001. Risk of death from methicillin-resistant *Staphylococcus aureus* bacteraemia: a meta-analysis. *Med J Aust* 175:264–267.

Williams RE, Jevons MP, Shooter RA, Hunter CJ, Girling JA, Griffiths JD, Taylor GW. 1959. Nasal staphylococci and sepsis in hospital patients. *Br Med J* 2:658–662. <https://doi.org/10.1136/bmj.2.5153.658>.

Wolk DM, Struelens MJ, Pancholi P, Davis T, Della-Latta P, Fuller D, Picton E, Dickenson R, Denis O, Johnson D, Chapin K. 2009. Rapid detection of *Staphylococcus aureus* and methicillin-resistant *S. aureus* (MRSA) in wound specimens and blood cultures: multicenter preclinical evaluation of the Cepheid Xpert MRSA/SA skin and soft tissue and blood culture assays. *J Clin Microbiol* 47:823–826. <https://doi.org/10.1128/JCM.01884-08>.

European Antimicrobial Resistance Surveillance Network (EARS-Net). 2018. European Centre for Disease Prevention and Control <http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/index.aspx>.

Kock, R. et al. 2010. Methicillin-resistant *Staphylococcus aureus* (MRSA): burden of disease and control challenges in Europe. *Eurosurveillance* **15**, 19688.

- Nielsen, K. L. et al. Fitness cost: a bacteriological explanation for the demise of the first international methicillin-resistant *Staphylococcus aureus* epidemic. *J. Antimicrob. Chemother.* **67**, 1325–1332 (2012).
- Rolain, J. M., Abat, C., Brouqui, P. & Raoult, D. 2015. Worldwide decrease in methicillin-resistant *Staphylococcus aureus*: do we understand something? *Clin. Microbiol. Infect.* **21**, 515–517.
- Styers, D., Sheehan, D. J., Hogan, P. & Sahm, D. F. 2006. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among *Staphylococcus aureus*: 2005 status in the United States. *Ann. Clin. Microbiol. Antimicrob.* **5**, 2.
- Talan, D. A. et al. 2011. Comparison of *Staphylococcus aureus* from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. *Clin. Infect. Dis.* **53**, 144–149.
- Moran, G. J. et al. 2006. Methicillin-resistant *S. aureus* infections among patients in the emergency department. *N. Engl. J. Med.* **355**, 666–674.